In conclusion, the present study has demonstrated, for the first time, that high glucose augments AGT in human RPTCs through HNF-5, a glucose-responsive transcriptional factor that functions on the AGT gene promoter, which provides a potential therapeutic target for DN in humans. The gene discussed is AGT; the disease is liver dysplastic nodule.